期刊文献+

汉族人群中二氢嘧啶脱氢酶基因多态性的初步研究 被引量:13

Survey of the polymorphism of dihydropyrimidine dehydrogenase gene in the Han nationality population
在线阅读 下载PDF
导出
摘要 目的:对中国汉族人群二氢嘧啶脱氢酶基因(DPYD)上与二氢嘧啶脱氢酶(DPD)活性相关的3个突变位点进行多态性调查。方法:采用PCR-SSCP-银染色法对122例健康汉族人DPYD的突变位点IVS14+1G→A、Exon13的A1627G和Exon11的G1156T进行筛查,并用限制性内切酶分析及DNA测序分析加以证实。结果:122例样本中有11例在Exon13的A1627G位点发生变异,限制性内切酶分析及DNA测序分析表明均为杂合型变异,其变异频率为4.5%;而IVS14+1G→A和Exon11的G1156T两个位点没有发现变异。结论:中国汉族人群DPYD的Exon13A1627G位点具有多态性;IVS14+1G→A和Exon11的G1156T两个位点没有多态性。 Objective:To survey the polymorphism of three mutation points on dihydropyrimidine dehydrogenase gene (DPYD) related to dihydropyrimidine dehydrogenase (DPD)aetivity in the Chinese Han nationality groups.Methods:One hundred and twenty-two healthy people belonging to Han nationality groups were select- ed to scan three mutation points of DPYD (IVS14+1G→A,Exonl3 A1627G and Exonll Gl156T) by PCR-SS- CP-silver staining method.We validated it by using restriction endonuelease analysis and DNA sequencing technique.Results:There were 11 variant bands of Exonl3 A1627G mutation among 122 samples and they were validated to be all heterozygote,whose allelie frequency was 4.5%.The IVS14+1G→A and Exonll G1156T point mutation were not found.Conclusion:Exonl3 A1627G possesses the polymorphie point in the Han nationality groups,while the IVS14+1G→A and Exonl1 G1156T are not.
出处 《中日友好医院学报》 2005年第4期202-204,207,F0002,共5页 Journal of China-Japan Friendship Hospital
基金 卫生部北京医院重点科研项目
关键词 基因多态性 二氢嘧啶脱氢酶 二氢嘧啶脱氢酶基因 gene polymorphism dihydropyrimidine dehydrogenase dihydropyrimidine dehydrogenase gene
  • 相关文献

参考文献14

  • 1Tuchman M,Stoeckeler JS,Kiang DT, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity[J].N Engl J Med, 1985,313:245-249.
  • 2Diasio RB,Beavers TL,Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity[J].J Clin Invest, 1988,81:47-51.
  • 3Harris BE, Carpenter JT, Diasio RB. Severe 5- fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency[J]. Cancer, 1991,68:499-501.
  • 4Wei X, McLeod HL, McMurrough J,et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity[J].J Clin Invest, 1996,98:610-615.
  • 5Kouwaki M, Hamajima N, Sumi S,et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity[J].Clin Cancer Res, 1998,4:2999-3004.
  • 6Vreken P, Van Kuilenburg ABP, Meinsma R,et al. Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene[J]. J Inher Metab Dis, 1997,20:335-338.
  • 7Vreken P,Van Kuilenburg ABP,Meinsma R,et al. Identification of a four-base deletion (del TCAT296-299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression[J].Hum Genet, 1997,100: 263-265.
  • 8Wei X, Elizondo G, Sapone A,et al. Characterization of the human dihydropyrimidine dehydrogenase gene[J]. Genomics,1998,51: 391-400.
  • 9Ridge SA,Sludden J,Wei X,et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer[J]. Br J Cancer, 1998,77:497-500.
  • 10Ridge S A, Sludden J, Brown O,et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects[J].Br J Clin Pharmacol,1998,46:151-156.

同被引文献227

引证文献13

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部